RB1 and cancer: As outlined earlier, CDK4/6 inhibitors inhibit the proliferation of cancer cells by suppressing retinoblastoma (RB) phosphorylation and maintaining the repressive effect of RB on the E2F family, thereby reducing the transcription of pro-proliferative proteins and inhibiting cell cycle progression.